shivaani kummar ohsu email shivaani kummar ohsu email

Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. Box 29017 Portland, OR 97296, Portland Office 2020 SW 4th Avenue Suite 900 Portland, OR 97201. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. OHSU is an equal opportunity affirmative action institution. OHSU is an equal opportunity affirmative action institution. Email: trials@ohsu.edu Call: 503-494-1080 Shivaani Kummar, MBBS is an Oncologist. A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Our ability to collaborate with academics and industries across the globe will be paramount to our success in developing new drugs for patients. Members receive periodic email communication about events, programming, news and funding opportunities. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. middlesex county community college nursing program nj Dr. Kummar loves to spend time with her family, read, and go for long walks. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. mollie hemingway face shivaani kummar ohsu email. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. General Information Email: ohsufinfo@ohsu.edu, Mailing Address Malhotras background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. Dive into details by clicking on the dots or, Knight Cancer Translational Oncology Program, Calculated based on number of publications stored in Pure and citations from Scopus, PQ3: Age-related immune deviation and cancer outcome, [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors, Understanding the origins of rapid recurrence of pancreatic cancer after resection. Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. As an oncologist, Dr. Kummar manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Their mission is clear: To give patients excellent care. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. Study Purpose. massachusetts vs washington state. Hung, M.D. Charles D. Blanke, M.D., F.A.C.P., F.A.S.C.O. Shivaani Kummar. (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734. Overall: 4.7 out of 5 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. February 17, 2023. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. What are the latest results? Keep me signed in. If you made any changes in Pure these will be visible here soon. The Knight Cancer Institutes Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. Local: (503) 228-1730 | Toll Free: (800) 462-6608 & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. Try restaurant style recipes at home. Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. Only fill in if you are not human. shivaani kummar ohsu email. Very few institutions do it well, but OHSU truly gets it, Kummar says. 2001-2023 OHSU. You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number - 503-314-7168). What sort of projects are you working on right now? She received her medical degree from Lady Hardinge Medical College and has been in practice for . These topic labels come from the works of this person. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. Malhotras impressive background in drug development will be key to cultivating this new center, says Druker, also the JELD-WEN Chair of Leukemia Research at OHSU. Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. OHSU is an equal opportunity affirmative action institution. NPI Lookup NPI Database. Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. We also share information about your use of our site with our trusted social media, advertising and analytics partners. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . . She runs early phase clinical trials evaluating new treatments while ensuring highest standards of patient safety. However, high costs, long development t My patients. 1. cleveland, tx funeral homes share dancing on ice app for ipad tweet exhaustive list of cushing's syndrome symptoms share. February 17, 2023. 23() 'Oregon Health & Science University Knight Cancer Institute(OHSU)' BAL0891 1 Shivaani Kummar (Principal Investigator, PI), OHSU 'Mary Crowley Cancer Research . Post author By ; aleko lm137 manual Post date July 1, 2022; police clearance certificate in saudi arabia . The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Support the Abortion Care and Training Fund. The units team of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Together their goal is to find a cure for cancer. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Accueil; Solution; Tarif; PRO; Mon compte; France; Accueil; Solution OHSU is an equal opportunity affirmative action institution. Clinical trials Drug development oncology. Professor of Medicine, OHSU. Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD The couple says their ultimate goal is to develop new effective therapies for cancer. We are thrilled he is able to co-lead this new venture. Dive into the research topics where Shivaani Kummar is active. Education & Training Oregon Health & Science University Fellowship, Hematology and Medical Oncology, 1995 - 1997 New York Presbyterian Hospital (Columbia Campus) Residency, Internal Medicine, 1990 - 1993 Harvard Medical School Class of 1989 She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 . They say they shared an interest in cancer drug discovery and development that grew after their marriage. (OHSU/Kristyna Wentz-Graff). bard college music faculty. Across OHSU, doctors and researchers are reimagining early disease detection. Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. She accepts multiple insurance plans. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. OHSU is an equal opportunity affirmative action institution. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. In 2014, the state of Oregon supported the OHSU Knight Cancer Challenge by providing $200 million in bonding to support building cancer research and clinical trial capacity. Dr. Shivaani Kummar, MD is a medical oncology specialist in Portland, OR. . Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. condition, procedure, doctor name. 2022 ASCO Annual Meeting - Poster Session . I am humbled and inspired by the courage, grace and feeling of altruism that I find in each and every patient who chooses to participate in these trials. Caring for them drives me to work harder to develop more effective treatments that are better tolerated. It is a privilege to be able to work in this field. Dr. what was bolivar's ultimate goal? L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, Clinical Cancer Research 13 (18), 5411-5417. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. He has the mindset and the clear vision to make that mindset a reality., Malhotra agrees: We speak the same language. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. Articles Cited by Public access. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. (44 Ratings, This philanthropy-fueled research revolution is already saving lives. The provider's speciality is Internal Medicine with a focus in Medical Oncology How many years of experience does Dr. Shivaani Kummar have? Hamburger Menu x Home (h.c.), Ph.D., FAACR. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX ( ) (MCI) 'BAL0891' 1 27 . 5 , IND transfer 4 . 23() 'Oregon Health . Spray Foam Equipment and Chemicals. S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, K Do, D Wilsker, J Ji, J Zlott, T Freshwater, RJ Kinders, J Collins, AP Chen, Journal of Clinical Oncology 33 (30), 3409. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. Drukers approach to team science is incorporated throughout the institutes infrastructure. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Kummars remarkable accomplishments, combined with her ability to connect with people and her clear vision for how to grow the hematology-oncology division, made her our top candidate. Share on email. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. Shivaani Kummar Dr. Kummar was recently appointed as Division Chief of Hematology and Oncology, and co-Director of the Center for Experimental Therapeutics, at the Oregon Health and Science University in Portland, Oregon. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Accepting new patients Our ability to move these projects forward and to take on new projects is limited by the available resources. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. Uncategorized . The two will co-lead the institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. 9842741222, 9942641222, 9842724434 chinamanpaversscc@gmail.com. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. Give Now. The field of oncology is so broad, and theres so much to be done, Kummar says. Where is Dr. Shivaani Kummar located? Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. Visit thebilling andinsurancesection of our sitefor more information. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. And to train and inspire the next generation of doctors and scientists. What excites you about coming to work in the morning? Title. Administrative Coordinator, Felicia Feingersch 2001-2023 OHSU. boundtree continuing education; can you be charged under ucmj after discharge OHSU Knight Cancer Institute leaders include some of the most distinguished doctors and scientists in the world. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. At the end of the day, we need to develop better treatment for cancer patients and the only way to build that is through collaboration within OHSU and with other academic centers, biotech and pharma companies., Team science can be a buzz word. We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. Dr. (OHSU/Joe Rojas-Burke). The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. We have a number of clinical trials investigating promising new strategies to treat cancer. Faculty and staff recruitment information. Her research interests focus on developing novel therapies for cancer. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography Dr. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. scripps institution of oceanography graduate programs; rosemont seneca advisors website Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. You may also qualify for Phase 1 Program trials. Cited by. In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. Cancer Early Detection Advanced Research Center, Adolescent and Young Adult Oncology Program, Social and Emotional Side Effects of Cancer, International Alliance for Early Cancer Detection (ACED), Lisa M. Coussens, M.D. OHSU Foundation P.O. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.